Whale Secures $60 Million to Expand its Enterprise AI Suite Globally
In its May 2025 Series C2 round, Whale brought in new strategic investors, including BOSCH Ventures, MTR Lab, Singtel Innov8, MDI Ventures, and Gentree Fund. This follows the Series C1 round completed in 2023 which had participation from existing investor Temasek and Linear Capital.
Products
AI to See, Hear, Express, and Think
Whale builds AI-native enterprise product solutions designed to help businesses automate operations, accelerate decision-making, and gain deeper customer insight. Its platform integrates advanced AI, IoT, and data infrastructure technologies—offering a secure and scalable foundation for intelligent business transformation.
With over 60 fine-tuned private AI models built specifically for enterprise use, Whale continues to invest heavily in generative AI, IoT infrastructure, and data operations.
Overview
Founded in 2017 and headquartered in Singapore, Whale supports over 600 enterprise customers across more than 20 countries. Its AI solutions power a diverse range of industries, including fashion, luxury, food and beverage, consumer electronics, retail, healthcare, and automotive.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
3 hours ago
- Korea Herald
Next Level Aviation® Completes Recap of Turning Rock Partners
NLA completed the full redemption of Turning Rock's preferred equity investment ahead of schedule , Fla., Aug. 5, 2025 /PRNewswire/ -- Next Level Aviation ® (NLA), a leader in the global distribution of used serviceable materials (USM) for all Boeing and Airbus commercial aircraft and associated jet engine platforms, has fully redeemed Turning Rock Partners' (TRP) 2019 preferred equity investment. NLA completed the full redemption of TRP's stake, ahead of schedule, in mid- June 2025. Next Level Aviation ® Chairman & CEO Jack Gordon stated, "We are extremely pleased to complete the full redemption of Turning Rock Partners. We again want to thank the TRP team for their financial and operational support during the investment period. We wish the entire TRP team the best, personally and with their portfolio investments, going forward." Mr. Gordon continued, "We would also like to thank the PNC Business Credit team again for providing the asset-based lending flexibility needed to complete this management led recap. Now that the recap is complete, 100% ownership of Next Level Aviation ® reverts to its founders. Management is in the process of evaluating the equity needs of the business going forward before choosing a new financial partner to assist us in taking the business to the next level." About Next Level Aviation ® Next Level Aviation ® is an ASA-100 accredited, and FAA Advisory Circular 00-56B compliant supplier stocking commercial aircraft/jet engine used serviceable material (USM) for all Boeing and Airbus aircraft platforms and associated jet engines. Next Level Aviation ® specifically focuses on stocking USM for the Boeing 737 and Airbus A320 families of aircraft and their associated jet engines, which currently make up about 65% of the global commercial fleet. Founded in March 2013 by Jack Gordon, Mike Dreyer, and Matt Dreyer, Next Level Aviation ® has grown into a top global supplier of commercial aircraft/jet engine used serviceable material.
Korea Herald
3 hours ago
- Korea Herald
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Seegene Inc., a global leader in molecular diagnostics, unveiled two new technologies at ADLM 2025 in Chicago (July 29–31) designed to advance laboratory automation and data-driven infectious disease monitoring. The company introduced CURECA™, world's first fully unattended PCR automation system, and STAgora™, a real-time data analytics platform intended to support earlier detection and precision care. Chairman Highlights Next Step in Molecular Diagnostics "With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." Today, most molecular testing systems remain only partially automated, dependent on skilled personnel for repetitive manual steps and fixed workflows that limit efficiency and scalability. CURECA™ Breaks the Limits of Automation to Reshape Global Diagnostics CURECA™ is the first system in the diagnostics industry designed to fully automate every step of PCR testing, including the traditionally manual pre-treatment stage. Seegene notes that achieving true full automation in diagnostics requires three key conditions: operation without highly trained professionals, continuous 24-hour processing, and uninterrupted specimen input. CURECA™ is designed to meet all three. Its dedicated module, CURECA™ Prep, processes a wide range of specimen types such as urine, blood, sputum, and stool, addressing one of the most persistent barriers to automation. With the module handling diverse specimen pre-treatment, the full CURECA™ system completes the entire PCR workflow from sample loading through nucleic acid extraction, amplification, and result analysis without manual intervention. The system is engineered for continuous 24-hour operation, aiming to minimize human error, improve workflow efficiency, and allow laboratories to allocate skilled staff to higher-value activities. Full automation has long been a challenge in diagnostics due to specimen variability and the reliance on trained personnel for repetitive pre-processing tasks. CURECA™ is intended to help laboratories overcome these constraints by providing a scalable and adaptable system that can be configured to fit different lab sizes and workflows. CURECA™ Prep could also potentially extend to other testing fields, such as clinical chemistry and immunodiagnostics, as Seegene continues to explore broader automation solutions. STAgora™ Transforms Diagnostic Data into Real-Time Clinical Intelligence STAgora™ is Seegene's latest platform, designed to collect and analyze PCR testing data in real time, providing laboratories with broader context to inform diagnostic workflows. The platform includes more than 40 analytical tools, offering functions such as infection trend tracking, hospital-level positivity monitoring, and multi-pathogen co-infection pattern analysis. Rather than serving as a simple data repository, STAgora™ is built as an integrated platform intended to help laboratories derive meaningful, aggregated insights from testing data. Today, individual test results often provide limited information without broader reference points. STAgora™ is designed to address this by enabling hospitals to build their own statistical datasets and compare aggregated data across institutions, helping them detect infection patterns faster and support more informed decision-making. The data shared through the platform is de-identified and formatted according to each institution's requirements, supporting secure, real-time exchange at local, national, or global levels. Advancing Toward a World Free from All Diseases Dr. Chun reiterated Seegene's long-term vision of building "a world free from diseases" noting that the introduction of CURECA™ and STAgora™ completes the company's five core technology pillars. These include Seegene's proprietary PCR technology, the SGDDS (Seegene Digitalized Development System) for automated assay development, its global Technology-Sharing Initiative, and now the addition of fully automated PCR testing and real-time data analytics capabilities. Industry experts at ADLM 2025 expressed strong interest in Seegene's new technologies. Jamel Giuma, President and CEO of Miami based laboratory IT consulting firm JTG Consulting Group, said, "I've attended many ADLM conferences over the years, and CURECA™ is one of the most innovative solutions I have seen so far. I believe it has the potential to simplify laboratory workflows, reduce the burden on lab personnel, and greatly enhance overall operational efficiency." "With CURECA™ and STAgora™, we're addressing long-standing barriers in molecular diagnostics," Dr. Chun added. "Just as smartphones and electric vehicles transformed their industries, we believe these technologies will redefine what is possible in diagnostic testing, helping laboratories worldwide achieve true automation, unlock the value of diagnostic data, and ultimately contribute to building a world free from diseases." Disclaimer CURECA™ and STAgora™ demonstrated at ADLM 2025 are pre-commercial technologies under development, not commercially available, and are not currently cleared for clinical diagnostic use in any jurisdiction.
Korea Herald
5 hours ago
- Korea Herald
Ubilink, Zettabyte, and WiAdvance Collaborate to Advance AI Computing in Taiwan
TAIPEI, Aug. 5, 2025 /PRNewswire/ -- WiAdvance Technology, an innovative cloud service provider under the Wistron Group, and Zettabyte Technology Corporation, a software solutions provider specializing in Zsuite, jointly announced today that they are initiating a collaborative evaluation with a leading AI supercomputing company. The three parties aim to establish a strategic partnership to enhance overall performance and application value in AI computing services. The Ubilink AI Center is equipped with 128 NVIDIA H100 GPU servers, delivering computing power up to 45.82 PetaFlops—offering world-class high-performance computing capabilities. The goal of this collaboration is to integrate the strengths of all three parties: Zettabyte's expertise in AI GPU infrastructure management, WiAdvance's extensive experience in enterprise system integration and cloud solutions, and Ubilink's robust computing infrastructure. The three companies are actively exploring potential collaboration models to accelerate AI innovation in Taiwan and provide comprehensive support for applications such as generative AI, deep learning, model training, and inference—empowering startups, enterprises, and research institutions alike. About Zettabyte Zettabyte is a global leader reshaping AI compute with high-performance, energy-efficient GPU infrastructure and full-stack software (GPU Infrastructure-as-a-Service, IaaS). Its turnkey platform, Zware, powers next-generation AI data centers through GPU Cloud, Managed Services, and sovereign-ready systems—built for scale, security, and sustainability. For more information, please visit About Ubilink Co., Ltd. is a joint venture between Foxlink Group and Shinfox Energy, Ubitus, established to advance Taiwan's AI infrastructure and supercomputing capabilities. Ubilink provides next-generation compute resources to support AI innovation across industries, from research to large-scale enterprise deployment. For more information, please visit About WiAdvance WiAdvance Technology, a subsidiary of Wistron Corporation, is an innovative cloud services company headquartered in Taiwan. Based on Cloud, Data and AI technology, WiAdvance provides cloud-based service and vertical solutions which suit various industries and operational scenarios, enabling the customers to boost the business in today's ever-changing world. WiAdvance boasts a robust cloud technology team and extensive experience in field deployment. For more information, please visit
